Skip to main content
. 2022 Jun 29;10(9):2452–2455.e3. doi: 10.1016/j.jaip.2022.06.020

Figure 1.

Figure 1

Anti-spike antibodies and pharmacokinetic modeling of anti-S-IgG immunity. Observed and predicted anti-S-IgG serum concentrations using subcutaneous immunoglobulin 2 (SCIG#2) with 12,413 IU/mL anti-S-IgG (blue line) (days 0-56) and SCIG#3 with 39,783 IU/mL (red line) (days 57-144). Blue dotted line indicates predicted anti-S-IgG steady-state through levels with SCIG#2 (predicted Ctrough about 665 IU/mL). Simulations show a predicted further increase in anti-S-IgG serum concentration after switching to SCIG#3 (red line) (predicted Ctrough approximately 2,100 IU/mL). Serum anti-S-IgG measurements on days 53 (under SCIG#2) (blue dots), 85, and 144 (under SCIG#3) (red triangles) confirmed good agreement with the model. Black dotted lines indicate upper and lower prediction intervals (dotted black lines).